Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Design Therapeutics, Inc. (DSGN) had Return on Tangible Equity of -8.09% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-17.64M |
|
-- |
|
-- |
|
$19.71M |
|
$-19.71M |
|
$2.07M |
|
$-17.64M |
|
$-17.64M |
|
$-17.64M |
|
$-17.64M |
|
$-17.64M |
|
$-17.64M |
|
$-19.71M |
|
$-19.70M |
|
61.43M |
|
61.43M |
|
$-0.29 |
|
$-0.29 |
|
| Balance Sheet Financials | |
$227.05M |
|
$0.82M |
|
$3.39M |
|
$230.44M |
|
$10.19M |
|
-- |
|
$2.20M |
|
$12.39M |
|
$218.05M |
|
$218.05M |
|
$218.05M |
|
62.44M |
|
| Cash Flow Statement Financials | |
$-16.43M |
|
$-7.59M |
|
$19.93M |
|
$16.86M |
|
$12.77M |
|
$-4.09M |
|
$3.92M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
22.28 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-16.43M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.09% |
|
|
Return on Tangible Equity |
-8.09% |
-7.65% |
|
-8.09% |
|
$3.49 |
|
$-0.27 |
|
$-0.27 |
|